Ixabepilone and triple-negative breast cancer

Excerpt:


J. Pharm. Pharmacogn. Res., vol. 12, no. 4, pp. 722-734, Jul-Aug 2024. DOI: https://doi.org/10.56499/jppres23.1869_12.4.722 Review Systematic review on the efficacy and safety of ixabepilone-based chemotherapy regimen in triple-negative breast cancer [Revisión sistemática sobre la eficacia y seguridad del régimen de quimioterapia basado en ixabepilona en el cáncer de mama triple negativo] Maghfira Rahma Azizah1, Halida … Continue reading Ixabepilone and triple-negative breast cancer

J. Pharm. Pharmacogn. Res., vol. 12, no. 4, pp. 722-734, Jul-Aug 2024.

DOI: https://doi.org/10.56499/jppres23.1869_12.4.722

Review

Systematic review on the efficacy and safety of ixabepilone-based chemotherapy regimen in triple-negative breast cancer

[Revisión sistemática sobre la eficacia y seguridad del régimen de quimioterapia basado en ixabepilona en el cáncer de mama triple negativo]

Maghfira Rahma Azizah1, Halida Adib Hanum1, Eviana Norahmawati2, Sharida Fakurazi3, Yoshiyuki Kawamoto4, Sofy Permana5, Edwin Widodo6, Agustina Tri Endharti7,8*

1Master Program in Biomedical Sciences, Faculty of Medicine, Universitas Brawijaya, Indonesia.

2Department of Anatomy Pathology, Faculty of Medicine, Universitas Brawijaya, Indonesia.

3Department of Human Anatomy, Faculty of Medicine and Health Science, Universiti Putra Malaysia, Serdang, Selangor, Malaysia.

4Department of Biomedical Sciences, Graduate School of Life and Health Sciences, Chubu University Japan.

5Department of Biology, Faculty of Mathematics and Natural Sciences, Universitas Brawijaya, Indonesia.

6Human Physiology Lab, Faculty of Medicine, Universitas Brawijaya, Indonesia.

7Department of Parasitology, Faculty of Medicine, Universitas Brawijaya, Indonesia.

8Biomedical Central Laboratory, Faculty of Medicine, Universitas Brawijaya, Indonesia.

*E-mail: tinapermana.fk@ub.ac.id

Abstract

Context: Triple-negative breast cancer (TNBC) has poor prognosis, high mortality, and recurrence rates. Ixabepilone or ixempra could be a promising agent for TNBC, especially in the taxane- and/or anthracycline-resistant population.

Aims: To evaluate the efficacy and safety of ixabepilone-based chemotherapy compared to ixabepilone-free chemotherapy in TNBC patients.

Methods: This review followed the preferred reporting items for systematic reviews and meta-analysis guidelines. The eligibility criteria included randomized control trials (RCTs) in 2013-2023 comparing ixabepilone-based with ixabepilone-free chemotherapy regimen in TNBC.

Results: This study identified four eligible RCTs. One study showed that patients treated with ixabepilone had a significant improvement in disease-free survival, had a better response, and a lower risk of disease recurrence compared to those treated with taxane-based regimen. However, two studies showed no differences in terms of overall survival (OS), disease-free survival, and pathological complete responses rates in both treatment arms. Ixabepilone addition to capecitabine significantly prolonged progression-free survival and objective response rate in TNBC patients, but did not significantly improve OS (n = 1).

Conclusions: The effectiveness and safety of ixabepilone-based chemotherapy versus ixabepilone-free treatment for triple-negative breast cancer (TNBC) patients vary among studies. More research is needed to better understand the effectiveness and safety of ixabepilone-based chemotherapy versus ixabepilone-free treatment in TNBC patients.

Keywords: effectivity; ixempra; toxicity; triple-negative breast cancer.

PDF Download

Resumen

Contexto: La unión de la glicoproteína 120 del virus de la inmunodeficiencia humana tipo 1 (VIH-1 gp120) al receptor CD4 de las células inmunitarias humanas es el inicio de la infección por VIH-1. La estimulación de la producción de especies reactivas de oxígeno (ROS) a través de la regulación al alza de la nicotinamida adenina dinucleótido fosfato (NADPH) oxidasa-2 (NOX-2) y -4 (NOX-4), y el citocromo P450 2E1 (CYP2E1) del virus puede ser un objetivo potencial para los agentes contra el VIH.

Contexto: El cáncer de mama triple negativo (CMTN) tiene mal pronóstico, alta mortalidad y tasas de recurrencia. La ixabepilona o ixempra podría ser un agente prometedor para el CMTN, especialmente en la población resistente a taxanos y/o antraciclinas.

Objetivos: Evaluar la eficacia y seguridad de la quimioterapia basada en ixabepilona en comparación con la quimioterapia sin ixabepilona en pacientes con TNBC.

Métodos: Esta revisión siguió los ítems de informe preferidos para revisiones sistemáticas y guías de metaanálisis. Los criterios de elegibilidad incluyeron ensayos controlados aleatorios (ECA) en 2013-2023 que compararon el régimen de quimioterapia basado en ixabepilona con el régimen de quimioterapia libre de ixabepilona en TNBC.

Resultados: Este estudio identificó cuatro ECA elegibles. Un estudio mostró que los pacientes tratados con ixabepilona tuvieron una mejora significativa en la supervivencia libre de enfermedad, tuvieron una mejor respuesta y un menor riesgo de recurrencia de la enfermedad en comparación con los tratados con régimen basado en taxanos. Sin embargo, dos estudios no mostraron diferencias en términos de supervivencia global (SG), supervivencia libre de enfermedad y tasas de respuestas patológicas completas en ambos brazos de tratamiento. La adición de ixabepilona a la capecitabina prolongó significativamente la supervivencia libre de progresión y la tasa de respuesta objetiva en pacientes con CMTN, pero no mejoró significativamente la SG (n = 1).

Conclusiones: La eficacia y la seguridad de la quimioterapia basada en ixabepilona frente al tratamiento sin ixabepilona en pacientes con cáncer de mama triple negativo (CMTN) varían según los estudios. Se necesitan más investigaciones para comprender mejor la eficacia y la seguridad de la quimioterapia basada en ixabepilona frente al tratamiento sin ixabepilona en pacientes con CMTN.

Palabras Clave: cáncer de mama triple negativo; eficacia; ixempra; toxicidad.

PDF Download

 

 
 
Citation Format: Azizah MR, Hanum HA, Norahmawati E, Fakurazi S, Kawamoto Y, Permana S, Widodo E, Endharti AT (2024) Systematic review on the efficacy and safety of ixabepilone-based chemotherapy regimen in triple-negative breast cancer. J Pharm Pharmacogn Res 12(4): 722–734. https://doi.org/10.56499/jppres23.1869_12.4.722
References

Adiputra PAT, Sudarsa IW (2021) Skoring prognostik survival pasien triple negative breast cancer berbasis immunoscore. J Bedah Nas 5(2): 65-75. https://doi.org/10.24843/JBN.2021.v05.i02.p05

Arnold M, Morgan E, Rumgay H, Mafra A, Singh D, Laversanne M, Vignat J, Gralow JR, Cardoso F, Siesling S, Soerjomataram I (2022) Current and future burden of breast cancer: Global statistics for 2020 and 2040. Breast 66: 15–23. https://doi.org/10.1016/j.breast.2022.08.010

Campone M, Lacroix-Triki M, Roca L, Spielmann M, Wildiers H, Cottu P, Kerbrat P, Levy C, Mayer F, Bachelot T, Wiston T, Eymard J-C, Uwer L, Machiels J-P, Verhoeven D, Jaubert D, Facchini T, Orfeuvre H, Canon J-L, Asselain B, Lemonnier J, Roché H (2016) UCBG intergroup: 3-years efficacy results of the Unicancer-PACS08 trial including poor prognosis patients treated with docetaxel or ixabepilone in adjuvant setting. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium. San Antonio, Philadelphia. Cancer Res 76 (4_Suppl.): P1-12-06. https://doi.org/10.1158/1538-7445.SABCS15-P1-12-06

Campone M, Lacroix-Triki M, Roca L, Spielmann M, Wildiers H, Cottu P, Kerbrat P, Levy C, Desmoulins I, Bachelot T, Winston T, Eymard JC, Uwer L, Duhoux FP, Verhoeven D, Jaubert D, Coeffic D, Orfeuvre H, Canon JL, Asselain B, Martin AL, Lemonnier J, Roché H (2018) UCBG 2-08: 5-year efficacy results from the UNICANCER-PACS08 randomised phase III trial of adjuvant treatment with FEC100 and then either docetaxel or ixabepilone in patients with early-stage, poor prognosis breast cancer. Eur J Cancer 103: 184–194. https://doi.org/10.1016/j.ejca.2018.06.025

Christie EL, Pattnaik S, Beach J, Copeland A, Rashoo N, Fereday S, Hendley J, Alsop K, Brady SL, Lamb G, Pandey A, deFazio A, Thorne H, Bild A, Bowtell DDL (2019) Multiple ABCB1 transcriptional fusions in drug resistant high-grade serous ovarian and breast cancer. Nat Commun 10: 1295. https://doi.org/10.1038/s41467-019-09312-9

Furlanetto J, Loibl S (2020) Optimal systemic treatment for early triple-negative breast cancer. Breast Care 15(3): 217–226. https://doi.org/10.1159/000508759

Gautama W (2022) Breast cancer in Indonesia in 2022: 30 years of marching in place. Indones J Cancer 16(1): 1-2. http://dx.doi.org/10.33371/ijoc.v16i1.920

Ge J, Zuo W, Chen Y, Shao Z, Yu K (2022) The advance of adjuvant treatment for triple-negative breast cancer. Cancer Biol Med 19(2): 187–201. https://doi.org/10.20892/j.issn.2095-3941.2020.0752

Ibrahim NK (2021) Ixabepilone: Overview of effectiveness, safety, and tolerability in metastatic breast cancer. Front Oncol 11: 617874. https://doi.org/10.3389/fonc.2021.617874

Ixempra (2015) IXEMPRA® (ixabepilone)— A non-taxane chemotherapy. Pharmacy Fact Sheet. R-PHARM US. https://www.ixempra.com/wp-content/uploads/Pharmacy_Fact_Sheet.pdf

Jassem J, Fein L, Karwal M, Campone M, Peck R, Poulart V, Vahdat L (2012) Ixabepilone plus capecitabine in advanced breast cancer patients with early relapse after adjuvant anthracyclines and taxanes: A pooled subset analysis of two phase III studies. Breast 21(1): 89–94. https://doi.org/10.1016/j.breast.2011.09.003

Li J, Ren J, Sun W (2017) Systematic review of ixabepilone for treating metastatic breast cancer. Breast Cancer 24(2): 171–179. https://doi.org/10.1007/s12282-016-0717-0

Lim B, Miller E, Lee HJ, Lulla A, Hernandez L, Gokare P (2014) Current treatment of early breast cancer: Adjuvant and neoadjuvant therapy. F1000Research 3: 198. https://doi.org/10.12688/f1000research.4340.1

Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. BMJ 339(7716): b2535. https://doi.org/10.1136/bmj.b2535

Osborne C, Challagalla JD, Eisenbeis CF, Holmes FA, Neubauer MA, Koutrelakos NW, Taboada CA, Vukelja SJ, Wilks ST, Allison MA, Reddy P, Sedlacek S, Wang Y, Asmar L, O’Shaughnessy J (2018) Ixabepilone and carboplatin for hormone receptor positive/HER2-neu negative and triple negative metastatic breast cancer. Clin Breast Cancer 18(1): e89–e95. http://dx.doi.org/10.1016/j.clbc.2017.07.002

PubChem (2023) Ixabepilone. https://pubchem.ncbi.nlm.nih.gov/compound/6445540 (Accessed 17 June 2023).

Rodriguez AA, Salazar N, Patel TA, Mejia JA, Froehlich A, Sneige N, Amin S, Weiss H, Rivera E, Chang JCN (2014) A randomized, parallel-arm, phase II trial to assess the efficacy of preoperative ixabepilone with or without cetuximab in patients with triple-negative breast cancer (TNBC). J Clin Oncol 32(15): 1133. https://doi.org/10.1200/jco.2014.32.15_suppl.1133

Rugo HS, Campone M, Amadori D, Aldrighetti D, Conte P, Wardley A, Villanueva C, Melisko M, McHenry MB, Liu D, Lee F, Pivot X (2013) A randomized, phase II, three-arm study of two schedules of ixabepilone or paclitaxel plus bevacizumab as first-line therapy for metastatic breast cancer. Breast Cancer Res Treat 139(2): 411–419. https://doi.org/10.1007/s10549-013-2552-8

Rugo HS, Roche H, Thomas E, Chung HC, Lerzo GL, Vasyutin I, Patel A, Vahdat L (2018) Efficacy and safety of ixabepilone and capecitabine in patients with advanced triple-negative breast cancer: A pooled analysis from two large phase III, randomized clinical trials. Clin Breast Cancer 18(6): 489–497. https://doi.org/10.1016/j.clbc.2018.07.024

Saura C, Tseng L-M, Chan S, Chacko RT, Campone M, Manikhas A, Nag SM, Leichman CG, Dasappa L, Fasching PA, Hurtado de Mendoza F, Symmans WF, Liu D, Mukhopadhyay P, Horak C, Xing G, Pusztai L (2013) Neoadjuvant doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early stage breast cancer and evaluation of βIII-tubulin expression as a predictive marker. Oncologist 18(7): 787–794. https://doi.org/10.1634/theoncologist.2013-0075

Tripathy D, Tolaney SM, Seidman AD, Anders CK, Ibrahim N, Rugo HS, Twelves C, Dieras V, Müller V, Tagliaferri M, Hannah AL, Cortés J (2019) ATTAIN: Phase 3 study of etirinotecan pegol versus treatment of physician’s choice in patients with metastatic breast cancer who have stable brain metastases previously treated with an anthracycline, a taxane, and capecitabine. Future Oncol 15(19): 2211-2225. https://doi.org/10.2217/fon-2019-0180

Wolff AC, Elizabeth Hale Hammond M, Allison KH, Harvey BE, Mangu PB, Bartlett JMS, Bilous M, Ellis IO, Fitzgibbons P, Hanna W, Jenkins RB, Press MF, Spears PA, Vance GH, Viale G, McShane LM, Dowsett M (2018) Human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology/ college of American pathologists clinical practice guideline focused update. J Clin Oncol 36(20): 2105–2122. https://doi.org/10.1200/JCO.2018.77.8738

Yardley DA, Arrowsmith ER, Daniel BR, Eakle J, Brufsky A, Drosick DR, Kudrik F, Bosserman LD, Keaton MR, Goble SA, Bubis JA, Priego VM, Pendergrass K, Manalo Y, Bury M, Gravenor DS, Rodriguez GI, Inhorn RC, Young RR, Harwin WN, Silver C, Hainsworth JD, Burris HA (2017) TITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early-stage triple-negative breast cancer. Breast Cancer Res Treat 164: 649–658. https://doi.org/10.1007/s10549-017-4285-6

Yin L, Duan JJ, Bian XW, Yu SC (2020) Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res 22: 61. https://doi.org/10.1186/s13058-020-01296-5

© 2024 Journal of Pharmacy & Pharmacognosy Research

Anti-dormant mycobacterial of marine-derived fungi
J. Pharm. Pharmacogn. Res., vol. 13, no. 1, pp. 16-26, Jan-Feb 2025. DOI: https://doi.org/10.56499/jppres24.1953_13.1.16 Original Article Activity of ethyl acetate extracts of marine-derived fungi against active and hypoxia-induced dormant Mycobacterium [Actividad de extractos de acetato de etilo de hongos de origen marino contra Mycobacterium latente activa e inducida por hipoxia] Muhammad Azhari1, Atik Pereztia Litanjuasari1, … Continue reading Anti-dormant mycobacterial of marine-derived fungi
Rift Valley fever virus RdRp inhibition by RNA polymerase inhibitors
J. Pharm. Pharmacogn. Res., vol. 13, no. 1, pp. 1-15, Jan-Feb 2025. DOI: https://doi.org/10.56499/jppres24.1967_13.1.1 Original Article In silico study of RNA polymerase inhibitor drugs for Rift Valley fever virus using RdRp protein as the target [Estudio in silico de fármacos inhibidores de la ARN polimerasa para el virus de la fiebre del valle del Rift … Continue reading Rift Valley fever virus RdRp inhibition by RNA polymerase inhibitors
Probable interaction between levothyroxine and Thymus vulgaris
J. Pharm. Pharmacogn. Res., vol. 12, no. 6, pp. 1196-1198, Nov-Dec 2024. DOI: https://doi.org/10.56499/jppres24.2008_12.6.1196 Case Report Probable interaction between levothyroxine sodium and thyme (Thymus vulgaris), about a case report [Interacción probable entre levotiroxina sódica y tomillo (Thymus vulgaris), sobre un reporte de caso] Nassima Elyebdri1,2*, Sihem Baba Ahmed1, Nessrine Abourejal1, Lotfi Loudjedi3, Assia Bououden3, Nour … Continue reading Probable interaction between levothyroxine and Thymus vulgaris

© 2013-2020 by the authors; licensee JPPRes, Antofagasta, Chile. This journal is an open-access journal distributed under the terms and conditions of the Creative Commons Attribution license-Non Commercial 4.0 international. The content on this site is intended for health professionals. If you are not a health professional, please talk to your doctor about any doubts or concerns regarding your health

Made with ♥ by AVAGAX Studio